Literature DB >> 12403977

From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.

Jill Heemskerk1, Allan J Tobin, Bernard Ravina.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12403977     DOI： 10.1038/nn931

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN： 1097-6256            Impact factor:   24.884


× No keyword cloud information.
  11 in total

Review 1.  In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?

Authors:  De-Maw Chuang; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-01       Impact factor: 13.382

Review 2.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

3.  Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program.

Authors:  Bernard Ravina; Scott Janis; Julianna Keleti; John M Marler
Journal:  NeuroRx       Date:  2004-07

4.  Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease.

Authors:  C J Yong-Kee; D Salomonczyk; J E Nash
Journal:  Neurotox Res       Date:  2010-04-02       Impact factor: 3.911

Review 5.  Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans.

Authors:  J Alex Parker; Sébastien Holbert; Emmanuel Lambert; Salima Abderrahmane; Christian Néri
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 6.  Strategic approaches to developing drug treatments for ALS.

Authors:  Andrea M Vincent; Stacey A Sakowski; Adam Schuyler; Eva L Feldman
Journal:  Drug Discov Today       Date:  2007-11-26       Impact factor: 7.851

7.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

8.  Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology.

Authors:  Irina G Stavrovskaya; Malini V Narayanan; Wenhua Zhang; Boris F Krasnikov; Jill Heemskerk; S Stanley Young; John P Blass; Abraham M Brown; M Flint Beal; Robert M Friedlander; Bruce S Kristal
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

9.  The role of positive selection in determining the molecular cause of species differences in disease.

Authors:  Jessica J Vamathevan; Samiul Hasan; Richard D Emes; Heather Amrine-Madsen; Dilip Rajagopalan; Simon D Topp; Vinod Kumar; Michael Word; Mark D Simmons; Steven M Foord; Philippe Sanseau; Ziheng Yang; Joanna D Holbrook
Journal:  BMC Evol Biol       Date:  2008-10-06       Impact factor: 3.260

10.  Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome.

Authors:  Yang Bian; Akio Masuda; Tohru Matsuura; Mikako Ito; Kazuya Okushin; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2009-01-15       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.